Arming androgen receptors to oppose oncogenic estrogen receptor activity in breast cancer

Summary Most breast cancers are driven by oncogenic activity of the estrogen receptor alpha (ER). Resistance to ER target therapies is the major cause of breast cancer death. Recently, there has been renewed interest in targeting the androgen receptor (AR) to treat ER-driven breast cancers. Herein,...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	British journal of cancer 2021-12, Vol.125 (12), p.1599-1601
Hauptverfasser:	Hickey, Theresa E., Dwyer, Amy R., Tilley, Wayne D.
Format:	Artikel
Sprache:	eng
Schlagworte:	631/67/1347 631/80/304 Androgen receptors Androgens Biomedical and Life Sciences Biomedicine Breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - genetics Cancer Research Comment Drug Resistance Epidemiology Estrogen receptors Estrogens Female Humans Life Sciences & Biomedicine Molecular Medicine Oncology Receptors, Androgen - metabolism Receptors, Estrogen - metabolism Science & Technology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Summary Most breast cancers are driven by oncogenic activity of the estrogen receptor alpha (ER). Resistance to ER target therapies is the major cause of breast cancer death. Recently, there has been renewed interest in targeting the androgen receptor (AR) to treat ER-driven breast cancers. Herein, we discuss evidence for an AR agonist, not antagonist, treatment strategy.
ISSN:	0007-0920 1532-1827
DOI:	10.1038/s41416-021-01478-8